Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Condition(s):Malignant Pleural MesotheliomaLast Updated:March 19, 2024Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Malignant Pleural MesotheliomaLast Updated:March 19, 2024Not yet recruiting
Condition(s):ObesityLast Updated:February 28, 2024Not yet recruiting
Condition(s):Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaLast Updated:March 5, 2024Recruiting
Condition(s):Neuroendocrine NeoplasmsLast Updated:March 25, 2024Recruiting
Condition(s):Hemophilia ALast Updated:January 25, 2024Recruiting
Condition(s):Prevention of Venous Thromboembolism; Congenital Heart Disease; Fontan Procedure; ChildrenLast Updated:March 27, 2024Not yet recruiting
Condition(s):Hypertrophic CardiomyopathyLast Updated:December 26, 2023Recruiting
Condition(s):Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric CancerLast Updated:March 13, 2024Recruiting
Condition(s):HealthyLast Updated:December 28, 2023Recruiting
Condition(s):Breast Cancer; Oligometastasis; Metastatic Breast CancerLast Updated:December 19, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.